Novel insights into the role of cardiotrophin-1 in cardiovascular diseases

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 2, 2009, Pages 142-148

  Calabro P ^a   Limongelli, G ^a   Riegler, L ^a   Maddaloni, V ^a   Palmieri, R ^a   Golia, E ^a   Roselli, T ^a   Masarone, D ^a   Pacileo, G ^a   Golino, P ^a   Calabro R ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biomarker; Cardiovascular disease; Cytokines; Inflammation; Interleukin 6 family

Indexed keywords

BIOLOGICAL MARKER; CARDIOTROPHIN 1;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE MARKER; ENDOCRINE FUNCTION; HEART; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VALVULAR HEART DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION;

MUS;

EID: 58149308294     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.11.002     Document Type: Review

References (74)

1. Clerico A. The increasing impact of laboratory medicine on clinical cardiology. Clin Chem Lab Med 41 7 (2003) 871-883
2. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113 19 (2006) 2335-2362
3. Collinson P.O., and Gaze D.C. Biomarkers of cardiovascular damage and dysfunction-an overview. Heart Lung Circ 16 3 (2007) S71-S82
4. Tsimikas S., Willerson J.T., and Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47 8 (2006) C19-C31
5. Amstrong E.J., Morrow D.A., and Sabatine M.S. Inflammatory biomarkers in acute coronary syndromes. Part IV: Matrix metalloproteinases and biomarkers of platelet activation. Circulation 113 9 (2006) e382-e385
6. Birner C.M., Ulucan C., Fredersdorf S., Rihm M., Lowel H., Stritzke J., et al. Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: superiority of BNP. Cytokine 40 2 (2007) 89-97
7. Richards A.M. Cardiotrophin-1: a new cardiac marker?. Clin Sci (Lond) 99 1 (2000) 91-92
8. Pennica D., King K.L., Shaw K.J., Luis E., Rullamas J., Luoh S.M., et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 92 4 (1995) 1142-1146
9. Saito M., Yoshida K., Hibi M., Taga T., and Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol 148 12 (1992) 4066-4071
10. Latchman D.S. Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther 85 1 (2000) 29-37
11. Kishimoto T., Akira S., Narazaki M., and Taga T. Interleukin-6 family of cytokines and gp130. Blood 86 4 (1995) 1243-1254
12. Pennica D., Shaw K.J., Swanson T.A., Moore M.W., Shelton D.L., Zioncheck K.A., et al. Cardiotrophin-1: biological activities and binding to the leukaemia inhibitory factor receptor/gp130 signalling complex. J Biol Chem 270 18 (1995) 10915-10922
13. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., and Graeve L. Interleukin-6 type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 2 (1998) 297-314
14. Kuwahara K., Saito Y., Kishimoto I., Miyamoto Y., Harada M., Ogawa E., et al. Cardiotrophin-1 phosphorylates Akt and BAD, and prolongs cell survival via a PI3 K-dependent pathway in cardiac myocytes. J Mol Cell Cardiol 32 8 (2000) 1385-1394
15. Yamauchi-Takihara K. Gp130-mediated pathway and left ventricular remodeling. J Card Fail 8 6 (2002) S374-378
16. Akira S., Nishio Y., Inoue M., Wang X.J., Wei S., Matsusaka T., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signalling pathway. Cell 77 1 (1994) 63-71
17. Wegenka U.M., Buschmann J., Lutticken C., Heinrich P.C., and Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13 1 (1993) 276-288
18. Nakajima T., Kinoshita S., Sasagawa T., Sasaki K., Naruto M., Kishimoto T., et al. Phosphorylation at threonine-235 by a ras-dependent mitogen activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 90 6 (1993) 2207-2211
19. Sheng Z., Knowlton K., Chen J., Hoshijima M., Brown J.H., and Chien K.R. Cardiotrophin-1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 272 9 (1997) 5783-5791
20. Railson J.E., Liao Z., Brar B.K., Buddle J.C., Pennica D., Stephanou A., et al. Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine 17 5 (2002) 243-253
21. Brar B.K., Stephanou A., Liao Z., O'Leary R.M., Pennica D., Yellon D.M., et al. Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. Cardiovasc Res 51 2 (2001) 265-274
22. Liao Z., Brar B.K., Cai Q., Stephanou A., O'Leary R.M., Pennica D., et al. Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 53 4 (2002) 902-910
23. Kunisada K., Tone E., Fujio Y., Matsui H., Yamauchi-Takihara K., and Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98 4 (1998) 346-352
24. Kunisada K., Negoro S., Tone E., Funamoto M., Osugi T., Yamada S., et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 97 1 (2000) 315-319
25. Takahashi N., Saito Y., Kuwahara K., Harada M., Tanimoto K., Nakagawa Y., et al. Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5/ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol 38 1 (2005) 185-192
26. Hilfiker-Kleiner D., Kaminski K., Podewski E., Bonda T., Schaefer A., Sliwa K., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 3 (2007) 589-600
27. Negoro S., Kunisada K., Tone E., Funamoto M., Oh H., Kishimoto T., et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47 4 (2000) 797-805
28. Negoro S., Kunisada K., Fujio Y., Funamoto M., Darville M.I., Eizirik D.L., et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104 9 (2001) 979-981
29. Hilfiker-Kleiner D., Hilfiker A., Fuchs M., Kaminski K., Schaefer A., Schieffer B., et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 95 2 (2004) 187-195
30. Negoro S., Oh H., Tone E., Kunisada K., Fujio Y., Walsh K., et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103 4 (2001) 555-561
31. Lopez N., Diez J., and Fortuno M.A. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine 30 5 (2005) 282-292
32. Brar B.K., Stephanou A., Pennica D., and Latchman D.S. CT-1 mediated cardioprotection against ischaemic re-oxygenation injury is mediated by PI3 kinase, Akt and MEK1/2 pathways. Cytokine 16 3 (2001) 93-96
33. Jin H., Yang R., Keller G.A., Ryan A., Ko A., Finkle D., et al. In vivo effects of cardiotrophin-1. Cytokine 8 12 (1996) 920-926
34. Marques J.M., Belza I., Holtmann B., Pennica D., Prieto J., and Bustos M. Cardiotrophin-1 is an essential factor in the natural defense of the liver against apoptosis. Hepatology 45 3 (2007) 639-648
35. Zheng X., Zhou D., Seow C.Y., and Bai T.R. Cardiotrophin-1 alters airway smooth muscle structure and mechanical properties in airway explants. Am J Physiol Lung Cell Mol Physiol 287 6 (2004) L1165-L1171
36. Zvonic S., Hogan J.C., Arbour-Reily P., Mynatt R.L., and Stephens J.M. Effects of cardiotrophin on adipocytes. J Biol Chem 279 46 (2004) 47572-47579
37. Oppenheim R.W., Wiese S., Prevette D., Armanini M., Wang S., Houenou L.J., et al. Cardiotrophin-1, a muscle-derived cytokine, is required for the survival of subpopulations of developing motoneurons. J Neurosci 21 4 (2001) 1283-1291
38. Forger N.G., Prevette D., deLapeyriere O., de Bovis B., Wang S., Bartlett P., et al. Cardiotrophin-like cytokine/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo. J Neurosci 23 26 (2003) 8854-8858
39. Pennica D., Swanson T.A., Shaw K.J., Kuang W.J., Gray C.L., Beatty B.G., et al. Human Cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine 8 3 (1996) 183-189
40. Sheng Z., Pennica D., Wood W.I., and Chien K.R. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 122 2 (1996) 419-428
41. Asai S., Saito Y., Kuwahara K., Mizuno Y., Yoshimura M., Higashikubo C., et al. The heart is a source of circulating cardiotrophin-1 in humans. Biochem Biophys Res Commun 279 2 (2000) 320-323
42. Latchman D.S. Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent. Int J Exp Pathol 80 4 (1999) 189-196
43. Stephanou A., Brar B., Heads R., Knight R.D., Marber M.S., Pennica D., et al. Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J Mol Cell Cardiol 30 4 (1998) 849-855
44. Liu J.C., He M., Wan L., and Cheng X.S. Heat shock protein 70 gene transfection protects rat myocardium cell against anoxia-reoxygeneration injury. Chin Med J (Engl) 120 7 (2007) 578-583
45. + channel-mediated hypoxic preconditioning. Cardiovasc Res 77 1 (2008) 126-133
46. Latchman D.S. Heat shock proteins and cardiac protection. Cardiovasc Res 51 4 (2001) 637-646
47. Wollert K.C., Taga T., Saito M., Narazaki M., Kishimoto T., Glembotski C.C., et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem 271 16 (1996) 9535-9545
48. Tsuruda T., Jougasaki M., Boerrigter G., Huntley B.K., Chen H.H., D'Assoro A.B., et al. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res 90 2 (2002) 128-134
49. Freed D.H., Borowiec A.M., Angelovska T., and Dixon I.M. Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signalling pathways. Cardiovasc Res. 60 2 (2003) 365-375
50. Jin H., Yang R., Ko A., Pennica D., Wood W.I., and Paoni N.F. Effects of cardiotrophin-1 on haemodynamics cardiac function in conscious rats. Cytokine 10 1 (1998) 19-25
51. Zolk O., Engmann S., Munzel F., and Krajcik R. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab 288 6 (2005) E1214-E1221
52. Hamanaka I., Saito Y., Nishikimi T., Magaribuchi T., Kamitani S., Kuwahara K., et al. Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. Am J Physiol Heart Circ Physiol 279 1 (2000) H388-H396
53. Souzeau E., Llamas B., Belanger S., Picard S., and Deschepper C.F. A genetic locus accentuates the effect of volume overload on adverse left ventricular remodeling in male and female rats. Hypertension 47 1 (2006) 128-133
54. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 9 7 (2007) 546-550
55. Pemberton C.J. Hypertension, cardiotrophin-1 and gp130: three points to heart failure?. J Hypertens 25 10 (2007) 2008-2010
56. Kurdi M., Randon J., Cerutti C., and Bricca G. Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol Cell Biochem 269 1 (2005) 95-101
57. Pemberton C.J., Raudsepp S.D., Yandle T.G., Cameron V.A., and Richards A.M. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 68 1 (2005) 109-117
58. Lopez B., Gonzalez A., Lasarte J.J., Sarobe P., Borras F., Diaz A., et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. J Hypertens 23 3 (2005) 625-632
59. Lopez B., Castellano J.M., Gonzalez A., Barba J., and Diez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension 50 5 (2007) 977-983
60. Gonzalez A., Lopez B., Martin-Raymondi D., Lozano E., Varo N., Barba J., et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 23 12 (2005) 2297-2304
61. Talwar S., Squire I.B., Davies J.E., and Ng L.L. The effect of valvular regurgitation on plasma Cardiotrophin-1 in patients with normal left ventricular systolic function. Eur J Heart Fail 2 4 (2000) 387-391
62. Talwar S., Downie P.F., Squire I.B., Davies J.E., Barnett D.B., and Ng L.L. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 3 1 (2001) 15-19
63. Harada M., Saito Y., Nakagawa O., Miyamoto Y., Ishikawa M., Kuwahara K., et al. Role of cardiac nonmyocytes in cyclic mechanical stretch-induced myocyte hypertrophy. Heart Vessels 12 suppl (1997) 198-200
64. Jougasaki M., Tachibana I., Luchner A., Leskinen H., Redfield M.M., and Burnett Jr. J.C. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation 101 1 (2000) 14-17
65. Zolk O., Ng L.L., O'Brien R.J., Weyand M., and Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 106 12 (2002) 1442-1446
66. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 38 5 (2001) 1485-1490
67. Jougasaki M., Leskinen H., Larsen A.M., Luchner A., Cataliotti A., Tachibana I., et al. Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure. Peptides 24 6 (2003) 889-892
68. Tsutamoto T., Asai S., Tanaka T., Sakai H., Nishiyama K., Fujii M., et al. Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail 9 10 (2007) 1032-1037
69. Talwar S., Squire I.B., Downie P.F., Davies J.E., and Ng L.L. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 84 4 (2000) 421-424
70. Talwar S., Squire I.B., O'Brien R.J., Downie P.F., Davies J.E., and Ng L.L. Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin Sci (Lond) 102 1 (2002) 9-14
71. Talwar S., Squire I.B., Downie P.F., O'brien R.J., Davies J.E., and Ng L.L. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond) 99 1 (2000) 83-88
72. Freed D.H., Moon M.C., Borowiec A.M., Jones S.C., Zahradka P., and Dixon I.M. Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. Mol Cell Biochem 254 1-2 (2003) 247-256
73. Wu L., Zhao L., Zheng Q., Shang F., Wang X., Wang L., et al. Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Mol Cell Biochem 284 1-2 (2006) 65-71
74. Liu J., Shen Q., and Wu Y. Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway. Life Sci 82 19-20 (2008) 991-996